Skandinaviska Enskilda Banken AB publ Lowers Stock Holdings in United Therapeutics Corporation $UTHR
Skandinaviska Enskilda Banken AB publ significantly reduced its stake in United Therapeutics Corporation, selling 78.9% of its holdings, or 70,978 shares, in the third quarter. Despite this, other institutional investors like Norges Bank and Invesco Ltd. increased their positions in the biotechnology company. United Therapeutics has also seen recent insider selling, with executives offloading shares, yet analysts maintain a "Moderate Buy" rating with a consensus target price of $509.50.
8,211 Shares in United Therapeutics Corporation $UTHR Bought by First National Bank of Omaha
First National Bank of Omaha has acquired a new stake of 8,211 shares in United Therapeutics (NASDAQ:UTHR) during the third quarter, valued at approximately $3.44 million. The biotechnology company maintains a "Moderate Buy" consensus rating from analysts with an average target price of $509.50, despite recent insider selling activity totaling around $218 million. Institutional investors and hedge funds collectively own 94.08% of the stock.
UBS reiterates Buy on United Therapeutics stock ahead of trials
UBS has reiterated a Buy rating and a $645.00 price target for United Therapeutics Corp. (NASDAQ: UTHR), representing a 34% upside. The firm anticipates upcoming Phase 3 study results and notes potential catalysts in 2026, despite recent share price dips due to seasonal sales and patent case delays. United Therapeutics also announced positive phase 1 study results for miroliverELAP and a new board appointment.
UBS reiterates Buy on United Therapeutics stock ahead of trials
UBS has reiterated its Buy rating and a $645.00 price target for United Therapeutics Corp., citing a 34% potential upside and the company's strong financial health. The firm anticipates upcoming Phase 3 study results and multiple catalysts in 2026, despite recent stock pullbacks due to expected Q4 Tyvaso sales below estimates. United Therapeutics also recently announced positive phase 1 study results for miroliverELAP and a new board appointment, further solidifying its growth prospects.
Tobam Buys 4,953 Shares of United Therapeutics Corporation $UTHR
Tobam recently increased its stake in United Therapeutics Corporation by 183.9%, acquiring an additional 4,953 shares, bringing its total holdings to 7,646 shares valued at $3.205 million. This coincides with other large institutions also boosting their positions in UTHR, which now has 94.08% institutional ownership. Despite significant insider selling over the past quarter, analysts have a "Moderate Buy" consensus rating for the biotechnology company.
Envestnet Asset Management Inc. Sells 15,252 Shares of United Therapeutics Corporation $UTHR
Envestnet Asset Management Inc. reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 20.9% in the third quarter, selling 15,252 shares. This sale left them with 57,820 shares valued at approximately $24.24 million. Despite this reduction from one institution, other large investors such as AQR Capital Management and Invesco Ltd. significantly increased their holdings, and institutional investors now own 94.08% of the company's stock. Analysts currently rate UTHR as a "Moderate Buy" with an average target price of $509.50.
MidWestOne Financial Group Inc. Raises Holdings in United Therapeutics Corporation $UTHR
MidWestOne Financial Group Inc. significantly increased its stake in United Therapeutics Corporation by 741.9% in Q3, now holding 9,446 shares valued at $3.96 million. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $509.50, despite recent insider share sales totaling over $242 million. Institutional investors own a substantial 94.08% of the company's stock.
United Therapeutics Corp. (NASDAQ:UTHR) Passes the "Caviar Cruise" Quality Investing Screen
United Therapeutics Corp. (NASDAQ:UTHR) has successfully passed the "Caviar Cruise" quality investing screen, indicating strong fundamentals for long-term investors. The company demonstrates maintained revenue and profit growth, outstanding capital utilization with a high ROIC, and robust financial soundness characterized by a debt-free balance sheet and high profit quality. These attributes suggest UTHR is a solid candidate for investors focused on quality and sustained performance.
Leuthold Group LLC Acquires Shares of 7,546 United Therapeutics Corporation $UTHR
Leuthold Group LLC initiated a new stake in United Therapeutics Corporation (NASDAQ: UTHR) during the third quarter, purchasing 7,546 shares valued at approximately $3.16 million. Institutional ownership of UTHR stands at 94.08%, with significant stake increases from firms like Invesco Ltd. and AQR Capital Management LLC. Analysts generally hold a "Moderate Buy" rating for UTHR, with an average price target of $509.50, and insider selling activity was also reported.
LSV Asset Management Sells 177,913 Shares of United Therapeutics Corporation $UTHR
LSV Asset Management reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 20.6% in the third quarter, selling 177,913 shares. Despite this, the stock retains a "Moderate Buy" rating from analysts with an average price target of $509.50. Company insiders have also sold a significant amount of stock, while institutional investors own a substantial portion of the shares.
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
United Therapeutics Corporation (Nasdaq: UTHR) announced it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release will be issued at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time accessible via their investor relations website. The company emphasizes its mission as a public benefit corporation, innovating for unmet medical needs and expanding the availability of transplantable organs.
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
United Therapeutics Corporation announced it will report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the market opens. A press release will be issued at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time. The webcast will be accessible via their website, and a rebroadcast will be available for one year.
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
United Therapeutics Corporation (Nasdaq: UTHR) announced it will report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the market opens. A press release will be issued at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time, accessible via the company's website. The company also highlighted its mission as a public benefit corporation focused on developing novel therapies and technologies for transplantable organs.
United Therapeutics Advances IPF Program With TETON-2 And PROLIFIC Milestones
United Therapeutics reported positive results from its TETON-2 study for inhaled treprostinil in idiopathic pulmonary fibrosis (IPF), suggesting it can stabilize lung function. The FDA also qualified the PROLIFIC Risk Score, a tool to identify high-risk IPF patients for more targeted clinical trials. These developments highlight United Therapeutics' clinical momentum in rare lung diseases, with a focus on how these advances will translate into broader clinical use and future research.
Profund Advisors LLC Sells 2,732 Shares of United Therapeutics Corporation $UTHR
Profund Advisors LLC significantly reduced its stake in United Therapeutics Corporation by 34.3% in Q3, selling 2,732 shares and retaining 5,244 shares valued at $2.20 million. This comes amidst broader insider selling activity, with COO Michael Benkowitz selling 22,500 shares for over $10.5 million, and a total of 498,714 insider shares sold for approximately $240.37 million in the past 90 days. Despite the selling, analysts maintain a "Moderate Buy" consensus with a target price of $509.50, while the stock trades near $473 with a $20.37 billion market cap.
Candriam S.C.A. Grows Stock Holdings in United Therapeutics Corporation $UTHR
Candriam S.C.A. significantly increased its stake in United Therapeutics Corporation (UTHR) by 48.3% in Q3 2025, now holding 123,387 shares valued at $51.7 million. Despite notable insider selling, Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $509.50, reflecting positive sentiment towards the biotechnology company. The article details institutional investment shifts, insider transactions, and analyst forecasts for UTHR.
Allianz Asset Management GmbH Trims Stake in United Therapeutics Corporation $UTHR
Allianz Asset Management GmbH reduced its stake in United Therapeutics Corporation by 29.7% in Q3, selling 19,018 shares and retaining 45,072 shares valued at approximately $18.9 million. Significant insider selling has also occurred, with COO Michael Benkowitz selling 22,500 shares for over $10.5 million. Despite this, analysts maintain a "Moderate Buy" rating for UTHR, with a consensus target price of $509.50.
BI Asset Management Fondsmaeglerselskab A S Cuts Stock Holdings in United Therapeutics Corporation $UTHR
BI Asset Management Fondsmaeglerselskab A S reduced its stake in United Therapeutics Corporation by 28.4% in the third quarter of 2025, selling 11,537 shares and holding 29,063 shares valued at approximately $12.18 million. Despite this reduction, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $509.50. The article also notes significant insider selling in the last 90 days, totaling over $260 million, while institutional ownership remains high at 94.08%.
Assessing United Therapeutics (UTHR) Valuation After Positive MiroliverELAP Phase 1 Safety And Survival Data
United Therapeutics (UTHR) has reported positive safety and survival data from its Phase 1 miroliverELAP trial, an external liver assist device for acute liver failure patients. Despite mixed recent stock momentum, longer-term shareholder returns are strong, and the company's valuation narrative suggests it is undervalued with a fair value target above its current share price. This outlook is supported by its innovation pipeline in regenerative medicine and organ manufacturing, though risks related to clinical trial outcomes remain.
Principal Financial Group Inc. Sells 5,583 Shares of United Therapeutics Corporation $UTHR
Principal Financial Group Inc. reduced its stake in United Therapeutics Corporation by 5.0%, selling 5,583 shares and now holding 105,767 shares valued at $44.34 million. Despite this, institutional ownership remains high at 94.08%, with other major institutions like Norges Bank and Invesco significantly increasing their holdings. Insiders, including the COO and EVP, have been net sellers, divesting a total of 537,914 shares worth $257.8 million in the past 90 days, though they still own 10.30% of the stock.
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co
Jan Malcolm, a Director at United Therapeutics Corp (UTHR), sold 50 shares of the company on February 3, 2026. This transaction brings her total ownership to 270 shares. The stock is currently trading at $474.23 and is considered Modestly Overvalued according to its GuruFocus Value.
Positive miroliverELAP Phase 1 Data Could Be A Game Changer For United Therapeutics (UTHR)
United Therapeutics (UTHR) recently reported positive phase 1 results for miroliverELAP, an external liver assist device, tested in five acute liver failure patients. While these early results are promising for the company's bioengineered organ alternatives, the immediate revenue impact is limited due to the early stage and small patient group. The company's investment narrative still heavily relies on its existing pulmonary hypertension franchise, alongside the long-term potential and inherent risks of its organ alternative programs.
Thrivent Financial for Lutherans Has $74.11 Million Stock Holdings in United Therapeutics Corporation $UTHR
Thrivent Financial for Lutherans reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 4.7% in the third quarter, reporting holdings valued at $74.11 million. Despite this reduction, institutional investors collectively own 94.08% of the stock, with several other hedge funds significantly increasing their positions. Analysts maintain a "Moderate Buy" consensus rating for United Therapeutics, with an average price target of $509.50, and recent insider selling activity has also been reported.
Summit Global Investments Sells 3,327 Shares of United Therapeutics Corporation $UTHR
Summit Global Investments reduced its stake in United Therapeutics Corporation by 18.1%, selling 3,327 shares and holding 15,006 shares valued at $6.29 million. Institutional investors collectively own 94.08% of the company, while insiders have also been selling shares, with a net sale of 566,864 shares over the last quarter. United Therapeutics reported Q3 EPS of $7.16, beating estimates, and analysts currently rate the stock a "Moderate Buy" with an average price target of $509.50.
A Look Back at Therapeutics Stocks' Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack
This article reviews the Q3 earnings of several therapeutics stocks, highlighting United Therapeutics (NASDAQ:UTHR) which had a softer quarter despite a stock rally, and Halozyme Therapeutics (NASDAQ:HALO) which delivered the strongest performance. It also covers the mixed results of BioMarin Pharmaceutical (NASDAQ:BMRN), Vertex Pharmaceuticals (NASDAQ:VRTX), and Biogen (NASDAQ:BIIB), providing an overview of their financial performance against analyst expectations.
Ruffer LLP Purchases 37,782 Shares of United Therapeutics Corporation $UTHR
Ruffer LLP significantly increased its stake in United Therapeutics Corporation (UTHR) by 351% in the third quarter, acquiring an additional 37,782 shares, bringing its total holding to 48,545 shares valued at approximately $20.35 million. Institutional ownership of UTHR is notably high at 94.08%, with major increases from other large investors like Norges Bank, Invesco Ltd., and AQR Capital Management LLC. Analyst sentiment for United Therapeutics is positive, with an average "Moderate Buy" rating and a consensus target price of $509.50, and some firms raising targets up to $645.
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)
This article reviews the Q3 performance of several therapeutics stocks, highlighting United Therapeutics (NASDAQ:UTHR) which reported revenues of $799.5 million, falling short of analyst expectations, yet its stock is up 15% since reporting. It also covers Halozyme Therapeutics (NASDAQ:HALO) as a top performer with strong revenue growth, alongside BioMarin Pharmaceutical (NASDAQ:BMRN), Novavax (NASDAQ:NVAX), and Vertex Pharmaceuticals (NASDAQ:VRTX), noting their individual Q3 results and stock movements. The sector as a whole experienced a mixed Q3 but saw stock prices increase by an average of 17.1% post-earnings.
Early miroliverELAP Safety Data Might Change The Case For Investing In United Therapeutics (UTHR)
United Therapeutics (UTHR) reported positive Phase 1 safety results for miroliverELAP, an external liver assist device, in five acute liver failure patients. While these early results strengthen the company's long-term organ manufacturing narrative, they are unlikely to impact short-term earnings due to the small sample size and lack of immediate revenue implications. The article suggests investors consider how this reinforces United Therapeutics' commitment to high-risk R&D in organ manufacturing and its potential impact on risk assessment.
Mitsubishi UFJ Trust & Banking Corp Sells 13,401 Shares of United Therapeutics Corporation $UTHR
Mitsubishi UFJ Trust & Banking Corp significantly reduced its stake in United Therapeutics Corporation, selling 13,401 shares and decreasing its holdings by 19.9%. Despite this, other institutional investors increased their positions, and analysts maintain a "Moderate Buy" consensus rating for UTHR with an average price target of $509.50. Insider selling has also been substantial, with COO Michael Benkowitz selling 22,500 shares recently, though insiders still own over 10% of the company.
Resona Asset Management Co. Ltd. Sells 3,558 Shares of United Therapeutics Corporation $UTHR
Resona Asset Management Co. Ltd. reduced its stake in United Therapeutics Corporation by 16.3% in the third quarter, selling 3,558 shares and retaining 18,282 shares valued at approximately $7.67 million. This comes amidst other hedge funds modifying their holdings and significant insider selling, with COO Michael Benkowitz selling 22,500 shares for $9.66 million. Analysts currently rate United Therapeutics as a "Moderate Buy" with an average target price of $509.50.
Strs Ohio Has $4.22 Million Stake in United Therapeutics Corporation $UTHR
Strs Ohio significantly increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 847.5% in the third quarter, bringing its total holdings to 10,062 shares valued at $4.22 million. Several other institutional investors also increased their positions, contributing to institutional ownership of approximately 94.08%. Wall Street analysts have a "Moderate Buy" rating for UTHR, with an average target price of $509.50, and the company recently beat quarterly EPS estimates.
World’s first FDA-cleared bioengineered liver trial meets survival goal
United Therapeutics (NASDAQ: UTHR) announced positive phase 1 study results for miroliverELAP®, an external liver assist product designed for patients with acute liver failure (ALF) who are ineligible for transplant. The study, which was the world’s first FDA-cleared clinical trial for a bioengineered liver, met its primary endpoint of patient survival during treatment, with no unexpected serious adverse events. This success paves the way for a phase 2 study, offering hope for ALF patients facing a critical shortage of donor organs.
Retirement Systems of Alabama Sells 18,709 Shares of United Therapeutics Corporation $UTHR
Retirement Systems of Alabama has reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 15.7%, selling 18,709 shares and now holding 100,273 shares valued at approximately $42.04 million. Despite significant insider selling and short interest, analysts maintain a "Moderate Buy" consensus rating with an average target price of $509.50. The biotechnology company, focused on life-threatening illnesses like pulmonary arterial hypertension, continues to attract institutional investors, with 94.08% of its stock owned by hedge funds and other institutional entities.
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
United Therapeutics announced positive results from its Phase 1 study of miroliverELAP®, an external liver assist product, for patients with various acute liver failure conditions. The study met its primary safety endpoint, showing survival during treatment with no unexpected serious adverse events. These results support advancing miroliverELAP® to a Phase 2 study, offering hope for patients who are not candidates for liver transplants amid a critical organ shortage.
Assessing United Therapeutics (UTHR) Valuation After Recent Share Price Swings
The article evaluates United Therapeutics (UTHR) stock valuation following recent share price volatility, noting a 9.5% undervaluation based on a fair value of $518.25. Despite short-term price swings, the company shows strong long-term returns and double-digit revenue and net income growth driven by an innovative pipeline, though future success depends on clinical and regulatory outcomes. Investors are encouraged to consider the company's potential in personalized and regenerative medicine.
Sawgrass Asset Management LLC Buys Shares of 27,337 United Therapeutics Corporation $UTHR
Sawgrass Asset Management LLC has acquired 27,337 shares of United Therapeutics Corporation (NASDAQ:UTHR) for approximately $11.46 million, representing 1.4% of Sawgrass's holdings and 0.06% of UTHR's outstanding shares. The biotechnology company recently beat EPS expectations but slightly missed on revenue, holding a "Moderate Buy" consensus rating with a target price of $509.50. Despite significant insider selling last quarter, institutions maintain a strong 94.08% ownership of the stock.
Emerald Mutual Fund Advisers Trust Acquires 2,894 Shares of United Therapeutics Corporation $UTHR
Emerald Mutual Fund Advisers Trust increased its stake in United Therapeutics Corporation by 112.2% in Q3, purchasing an additional 2,894 shares to own a total of 5,474 shares valued at $2.295 million. Despite insider selling activity totaling $9.66 million by COO Michael Benkowitz and $266.25 million by other insiders over the past 90 days, institutional ownership remains high at 94.08%. United Therapeutics (NASDAQ: UTHR) reported strong Q3 earnings, beating EPS estimates, and holds a consensus "Moderate Buy" rating with an average price target of $509.50.
Universal Beteiligungs und Servicegesellschaft mbH Reduces Stake in United Therapeutics Corporation $UTHR
Universal Beteiligungs und Servicegesellschaft mbH decreased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 10.6% in the third quarter of 2025, selling 4,619 shares and valuing its remaining 39,075 shares at $16.38 million. Despite this reduction, other institutional investors increased their holdings, and insider selling has also been notably high. The stock maintains a "Moderate Buy" consensus rating from analysts with an average price target of $509.50.
Rakuten Investment Management Inc. Makes New $1.82 Million Investment in United Therapeutics Corporation $UTHR
Rakuten Investment Management Inc. has initiated a new position in United Therapeutics Corporation (NASDAQ:UTHR) with an investment of $1.82 million, acquiring 4,349 shares during the third quarter. Despite significant insider selling totaling $266.25 million over the past 90 days, analysts generally maintain a "Moderate Buy" rating with a consensus target price of $509.50. United Therapeutics recently exceeded EPS estimates but fell slightly short on revenue expectations.
United Therapeutics Appoints Kevin J. Tracey To Board
United Therapeutics Corporation (Nasdaq: UTHR) announced the appointment of Kevin J. Tracey, M.D., to its Board of Directors. Dr. Tracey is the President, CEO, and Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research, bringing extensive scientific leadership, entrepreneurial experience, and groundbreaking research expertise in inflammation and bioelectronic medicine. His background is expected to provide invaluable guidance to United Therapeutics' mission in developing therapies for rare pulmonary diseases and organ manufacturing.
United Therapeutics appoints biomedical research leader to board By Investing.com
United Therapeutics Corporation (NASDAQ: UTHR) has appointed Dr. Kevin J. Tracey, a renowned biomedical research leader, to its Board of Directors. Dr. Tracey brings extensive expertise in inflammation and bioelectronic medicine research, along with entrepreneurial experience. This appointment is part of the company's board refreshment efforts and aims to strengthen its focus on developing therapies for rare pulmonary diseases and organ manufacturing development.
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
United Therapeutics Corporation (Nasdaq: UTHR) has appointed Kevin J. Tracey, M.D., to its Board of Directors. Dr. Tracey brings extensive experience as President, CEO, and Distinguished Chair in Medical Research at The Feinstein Institutes; his expertise in inflammation and bioelectronic medicine, along with his entrepreneurial background, is expected to provide invaluable guidance. This appointment continues the company's commitment to board refreshment and leveraging scientific leadership for its mission to advance therapies for rare pulmonary diseases and organ manufacturing.
United Therapeutics appoints new director, updates bylaws
United Therapeutics (UTHR) has expanded its board to 13 members with the appointment of Kevin J. Tracey, M.D., a notable researcher in inflammation and bioelectronic medicine. Concurrently, the company enacted an eleventh restatement of its bylaws to enhance shareholder influence by introducing a cure process for director nomination deficiencies, removing supermajority board vote requirements on routine matters, and reducing the shareholder voting threshold for bylaw amendments to a simple majority.
United Therapeutics appoints biomedical research leader to board
United Therapeutics Corporation has appointed Dr. Kevin J. Tracey, a notable biomedical research leader, to its Board of Directors. Dr. Tracey brings extensive experience in scientific leadership and bioelectronic medicine research. This appointment is part of the company's ongoing board refreshment efforts as it continues to advance its therapeutic pipeline for rare pulmonary diseases and organ manufacturing development programs.
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
United Therapeutics Corporation announced the appointment of Kevin J. Tracey, M.D., to its Board of Directors on January 21, 2026. Dr. Tracey brings extensive scientific leadership, entrepreneurial experience, and research expertise in inflammation and bioelectronic medicine. His background is expected to provide invaluable guidance to United Therapeutics' mission in developing therapies for rare pulmonary diseases and organ manufacturing.
Nordea Investment Management AB Has $1.73 Million Stock Holdings in United Therapeutics Corporation $UTHR
Nordea Investment Management AB significantly reduced its stake in United Therapeutics Corporation (NASDAQ: UTHR) by 62.4% in Q3, now owning 4,106 shares valued at $1.73 million. This comes as company insiders have been heavy net sellers, disposing of over $269 million worth of shares in the past three months. Despite insider selling, Wall Street analysts maintain a "Moderate Buy" consensus rating with a consensus price target of $509.50.
United Therapeutics Corporation $UTHR Shares Bought by Seizert Capital Partners LLC
Seizert Capital Partners LLC increased its stake in United Therapeutics Corporation by 17.1% during the third quarter, holding 146,991 shares worth approximately $61.62 million. This move contributes to a high institutional ownership of about 94.08% for UTHR. The company reported strong Q3 EPS but experienced significant insider selling totaling over $269 million in the last 90 days.
Marquette Asset Management, LLC Buys 1 Shares of United Therapeutics Corp (UTHR)
Marquette Asset Management, LLC has increased its stake in United Therapeutics Corp (UTHR) by purchasing an additional 1 share, bringing its total holdings to 810 shares valued at approximately $394,670. Other institutional investors like Perigon Wealth Management, LLC, EARNED WEALTH ADVISORS, LLC, and NISA INVESTMENT ADVISORS, LLC also initiated or increased their positions in UTHR. The article also provides UTHR's financial performance data, including its 52-week price range, moving averages, market capitalization, and recent earnings results.
Sumitomo Mitsui Trust Group Inc. Trims Holdings in United Therapeutics Corporation $UTHR
Sumitomo Mitsui Trust Group Inc. decreased its stake in United Therapeutics Corporation by 5.5% in the third quarter of 2025, selling 5,546 shares and retaining 94,702 shares valued at approximately $39.7 million. Despite this reduction, other institutional investors have increased their holdings, and analysts maintain a "Moderate Buy" rating for UTHR with a consensus target price of $509.50. The biotechnology company recently reported stronger-than-expected EPS and its COO sold a significant number of shares.
Polaris Capital Management LLC Sells 5,600 Shares of United Therapeutics Corporation $UTHR
Polaris Capital Management LLC reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 4.4%, selling 5,600 shares, but UTHR remains its sixth-largest holding. Despite recent insider selling, Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $509.50. United Therapeutics reported strong quarterly earnings, beating analyst estimates, and analysts anticipate continued EPS growth for the current year.
